Can we provide our own T-cells or patient-derived antibodies for use in your models?

Absolutely. Our platforms are flexible. We frequently collaborate with clients to incorporate their unique materials, such as purified T-cell populations, monoclonal antibodies, or patient serum samples, into the study. Let's discuss the specifics of your materials.

We are studying a specific signaling pathway. Can the model be customized for our needs?

Yes, customization is one of our core strengths. We can modify our models to include reporter cell lines, incorporate genetic knockdowns (siRNA/shRNA), or develop specialized assays to monitor the activity of your pathway of interest. We encourage you to reach out to our scientific team to discuss how we can build a model that fits your project perfectly.

Can the models be used to screen for complement inhibitors?

Absolutely. Our AMAN and MFS models are particularly well-suited for testing the efficacy of complement inhibitors, such as C5-targeting antibodies like eculizumab, in preventing nerve damage.

Why is early detection of GBS so important?

Studies, including mathematical modeling of disease progression, suggest that early detection and intervention provide a significantly greater chance of recovery and can reduce the risk of severe, long-term disability. Our models can help identify biomarkers to facilitate this.

How do I start a project with Creative Biolabs?

Simply use the contact form on this page or email our business development team. A PhD-level scientist will schedule a no-obligation teleconference to discuss your research goals and how our models can help you achieve them.

Online Inquiry

Guillain-Barré Syndrome (GBS) Cell Model Products

Introduction Types Advantages Applications FAQs Related Product Sections Product List

Introduction

Guillain-Barré Syndrome (GBS) is a severe and complex autoimmune disorder of the peripheral nervous system (PNS). The rapid onset of muscle weakness and paralysis presents a significant clinical challenge, with approximately 25% of patients requiring artificial ventilation and a mortality rate as high as 10%. Understanding the intricate cell-to-cell interactions that drive this disease is paramount for developing effective new therapies.

At Creative Biolabs, we recognize that dissecting the complex interplay between T cells, B cells, macrophages, and complement components in GBS requires sophisticated and clinically relevant in vitro tools. We have leveraged our deep expertise in neuroimmunology to develop a comprehensive portfolio of GBS cell models that provide a powerful platform for your research and drug discovery programs. Contact us to collaborate with our expert team; let's begin with a comprehensive discussion about your GBS project and a customized quotation.

Alternatively, specific offerings can be found by directly consulting our Product List.

Types

We offer a tiered range of models to suit your experimental needs and budget.

Types	Description
Schwann Cell / Neuron Monocultures	Ideal for baseline toxicity studies and investigating the direct effects of insults on neural cells.
Immune-Neural Co-Culture Systems	AIDP Demyelinating Models: Featuring Schwann cells co-cultured with activated, myelin-specific T cells and macrophages to model inflammatory demyelination. AMAN Axonal Models: Featuring neurons cultured with patient-derived anti-ganglioside antibodies (e.g., anti-GM1, anti-GD1a) and active complement to model direct axonal injury at the nodes of Ranvier.
Multi-Cellular Microphysiological Systems	These are our most advanced platforms, integrating multiple immune and neural cell types to provide a comprehensive view of GBS pathology.
Custom Patient-Derived Models	Collaborate with our scientists to build a unique model using cells from specific GBS patient cohorts to explore hypotheses related to genetics, age, or disease triggers.

Advantages

Gain a competitive edge in your research with models that offer unparalleled biological relevance.

High Clinical Translatability

By using human cells and mimicking the disease's cellular microenvironment, our models provide data that is more predictive of clinical outcomes compared to traditional animal models.

Accelerate Drug Discovery

Rapidly screen therapeutic candidates—from small molecules to biologics like complement inhibitors—in a controlled, reproducible, and human-relevant system.

Unravel Complex Mechanisms

Dissect the specific roles of molecular mimicry, T cell activation, antibody-mediated damage, and complement fixation in a way that is not possible with less complex systems.

Reduce Reliance on Animal Models

Our advanced in vitro platforms provide a robust alternative to EAN models, aligning with the 3Rs principles (Replacement, Reduction, Refinement) while offering superior mechanistic clarity.

Research & Development Applications

Our advanced GBS cell models are engineered to address the most critical questions in neuroimmunology research and therapeutic development.

Applications	Description
Preclinical Drug Screening and Validation	Utilize our human-relevant platforms to assess the efficacy of novel therapeutic agents. These models are ideal for evaluating compounds designed to mitigate inflammatory demyelination driven by T-cells, prevent antibody-mediated axonal injury, or block the terminal complement cascade.
Elucidation of Therapeutic Mechanisms	Go beyond efficacy to dissect the precise molecular pathways of your lead candidates. Our systems allow for detailed investigation into whether a compound works by suppressing pathogenic Th1/Th17 cytokine profiles, enhancing the function of regulatory T cells (Tregs), or inhibiting macrophage-mediated myelin stripping.
Modeling Disease Pathogenesis	Investigate the fundamental etiological links and cellular cascades that initiate GBS. This includes modeling the molecular mimicry hypothesis following infections with pathogens like Campylobacter jejuni or Zika virus, and dissecting the distinct roles of various immune subsets, from γδ T cells to effector T cells targeting specific myelin proteins.
Identification of Novel Biomarkers	Analyze the cellular secretome and cell-surface markers within our controlled co-culture environments. This application is designed to uncover new, mechanistically-linked biomarkers that could facilitate earlier diagnosis—a critical factor for improving patient outcomes —and monitor therapeutic responses.
Stratified and Precision Medicine Research	Develop models that reflect the heterogeneity of the GBS patient population. This includes creating systems to explore why disease severity is greater in older individuals by incorporating elements of an aging immune system, or to compare drug responses between the demyelinating (AIDP) and axonal (AMAN) variants of the disease.

A picture that presents the Immunopathological mechanisms involved in Guillain–Barré syndrome. (Shastri, et al., 2023) (OA Literature)

Fig.1 Immunopathological mechanisms involved in Guillain–Barré syndrome.¹

FAQs

Can we provide our own T-cells or patient-derived antibodies for use in your models?
Absolutely. Our platforms are flexible. We frequently collaborate with clients to incorporate their unique materials, such as purified T-cell populations, monoclonal antibodies, or patient serum samples, into the study. Let's discuss the specifics of your materials.
We are studying a specific signaling pathway. Can the model be customized for our needs?
Yes, customization is one of our core strengths. We can modify our models to include reporter cell lines, incorporate genetic knockdowns (siRNA/shRNA), or develop specialized assays to monitor the activity of your pathway of interest. We encourage you to reach out to our scientific team to discuss how we can build a model that fits your project perfectly.
Can the models be used to screen for complement inhibitors?
Absolutely. Our AMAN and MFS models are particularly well-suited for testing the efficacy of complement inhibitors, such as C5-targeting antibodies like eculizumab, in preventing nerve damage.
Why is early detection of GBS so important?
Studies, including mathematical modeling of disease progression, suggest that early detection and intervention provide a significantly greater chance of recovery and can reduce the risk of severe, long-term disability. Our models can help identify biomarkers to facilitate this.
How do I start a project with Creative Biolabs?
Simply use the contact form on this page or email our business development team. A PhD-level scientist will schedule a no-obligation teleconference to discuss your research goals and how our models can help you achieve them.

The path to a cure for Guillain-Barré Syndrome begins with understanding its fundamental biology. Creative Biolabs provides the robust, clinically relevant cell models necessary to unlock these mechanisms and test the next generation of therapies. We are more than a service provider; we are your scientific partner. Contact our team of neuroimmunology experts today to design the perfect GBS model for your research.